Zoledronic Acid Injection, Solution
Product Images NDC 68083-135

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zoledronic Acid (NDC 68083-135). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zoledronic-spl-carton (Zoledronic Spl Carton)

The packaging label for Zoledronic Acid Injection, 5 mg/100 mL (0.05 mg/mL) solution for intravenous infusion by Gland Pharma Limited. It is presented in a 100 mL single dose vial, sterile solution in a clear glass vial. The label includes instructions to dispense the accompanying Medication Guide to each patient and features a barcode, lot and expiration placeholders, and storage directions.*

FDA Label Image

Zoledronic-spl-container (Zoledronic Spl Container)

Label for Zoledronic Acid Injection, 5 mg/100 mL (0.05 mg/mL) sterile solution for intravenous infusion. The label indicates a 100 mL single dose vial, with usage instructions, storage conditions at 2°C to 25°C, and a warning not to mix with calcium-containing solutions. Manufactured by Gland Pharma Limited, Hyderabad, India. Includes barcode and lot/expiration date fields.*

FDA Label Image

Zoledronic-spl-structure (Zoledronic Spl Structure)

Chemical structure of Zoledronic Acid showing its molecular framework with two phosphonic acid groups and an imidazole ring, representing the active ingredient in the drug Zoledronic Acid injection solution.*

FDA Label Image

Zoledronic-spl-graph1 (Zoledronic Spl Graph1)

A line graph depicting time to first hip fracture in months comparing Zoledronic Acid injection, solution 5 mg/100 mL with placebo. The x-axis shows time in months up to 36, and the y-axis shows the cumulative incidence of hip fractures. Two lines represent the groups, with a stratified log-rank test p-value of 0.0024 indicating statistical comparison between Zoledronic Acid and placebo.*

FDA Label Image

Zoledronic-spl-graph2 (Zoledronic Spl Graph2)

Two bar charts comparing Zoledronic Acid and Risedronate over time. The first chart shows therapeutic response rates (%) increasing at various time points (days 10 to 182). The second chart presents serum alkaline phosphatase (SAP) normalization percentages increasing over a similar timeline (days 28 to 182). Zoledronic Acid consistently shows higher values than Risedronate, with statistically significant differences noted (P < 0.001).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.